Drug Profile
Research programme: anti-CD9 antibodies - ARIUS
Alternative Names: AR40A746.2.3Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ARIUS Research
- Class Monoclonal antibodies
- Mechanism of Action CD9 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Canada (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Canada (Parenteral)
- 24 Sep 2008 ARIUS Research has been acquired by Roche